Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.28 per share a year ago.
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Big Money Keeps Buying Corcept
Corcept Therapeutics Incorporated (CORT) shares rise on treatment advances, Big Money buys.
Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are OPFI, CORT, DXPE, PPTA, GHM.
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Corcept Therapeutics Generating Strong Revenue And Profit Growth
Corcept's sole drug, Korlym, treats Cushing Syndrome, a more prevalent condition than previously known, driving strong revenue and profit growth. A new market for Corcept's medications, diabetics, is poised to take the company to the next level. Long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant, which could expand market reach beyond Korlym.
Medical Stock Soars To Highs As Cortisol Screening Grows
Corcept Therapeutics makes drugs that modulate cortisol. The post Medical Stock Soars To Highs As Cortisol Screening Grows appeared first on Investor's Business Daily.
Corcept Submits Application for Another Cushing's Syndrome Drug
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.
Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
